1. Acquired SERPINC1/antithrombin deficiency during oral contraceptive consumption: a case report
- Author
-
D. Denora, M. V. Di Rosa, N. Altamura, F. Pellicori, P. Vinci, U. G. Sisto, F. Spanò, F. G. Di Girolamo, N. Fiotti, and G. Biolo
- Subjects
Acquired SERPINC1 ,Oral contraceptives ,Antithrombin deficiency ,Thrombophilia ,D-dimer ,Case report ,Medicine - Abstract
Abstract Background SERPINC1 is a glycoprotein that regulates blood coagulation. SERPINC1 congenital or acquired deficiencies represent a significant risk factor for thromboembolic disease. SERPINC1 acquired defects are observed in very few cases and can occur in many clinical conditions such as treatment with l-asparaginase or oral contraceptive (particularly estrogen derivatives), but these conditions are not routinely investigated. Case presentation A 50-year-old Caucasian woman who took gestodene 75 µg/ethinylestradiol 20 µg as oral contraceptive, was sent to our thrombophilia clinic because, on thrombophilia testing, a reduction of SERPINC1 (74%) and a slight increase in circulating D-dimer and homocysteine were found. We investigated triggers of such SERPINC1 reduction, and identified gestodene 75 µg/ethinylestradiol 20 µg use as the most likely candidate. Two months after the discontinuation of the oral contraceptive, SERPINC1 value returned to normal (92%) and D-dimer and homocysteine were normalized. Conclusion Each patient has a different sensitivity to contraceptive use. Genetic (or epigenetic) regulation of anticoagulant proteins might account for a different rate of consumption of anticoagulant proteins as oral contraceptives and probably determine the susceptibility to thrombotic events.
- Published
- 2023
- Full Text
- View/download PDF